Cardiology

Pacemaker Implantation in India and UAE | Complete Patient Guide

Pacemaker implantation is a life-saving cardiac procedure in which a small electronic device is surgically placed beneath the skin to regulate abnormal heart rhythms (bradyarrhythmias and certain tachyarrhythmias), restoring adequate cardiac output and preventing syncope, heart failure progression, and sudden cardiac death. Modern device therapy — including single-chamber, dual-chamber, biventricular (CRT-P), and leadless pacemakers — achieves procedural success rates exceeding 98% in experienced hands, with significant improvements in quality of life documented within weeks of implantation. GAF Healthcare connects international patients with JCI- and NABH-accredited cardiac centres in India and JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi, offering world-class electrophysiology expertise, transparent pricing, and end-to-end care coordination so patients can focus entirely on recovery.

Hospital Stay

2–4 days

Success Rate

99%

Available in

India & UAE

Pacemaker Implantation in India

Get Pacemaker Implantation at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.

Pacemaker Implantation in UAE

Pacemaker Implantation at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.

Overview

Hospital Stay: 2–4 days • Total Stay in Country (Fit-to-Fly): 2–3 weeks • Success Rate: 98–99%

What Is It?

The heart's electrical conduction system — comprising the sinoatrial (SA) node, atrioventricular (AV) node, His-Purkinje network, and ventricular myocardium — orchestrates the rhythmic contraction that sustains circulation. When intrinsic automaticity or conduction velocity falls below physiological thresholds, the result is bradycardia (typically defined as a resting heart rate below 40–50 beats per minute with symptoms), heart block (first-, second-, or third-degree), sick sinus syndrome, or chronotropic incompetence. These disorders manifest clinically as fatigue, exertional dyspnoea, pre-syncope, frank syncope (Stokes-Adams attacks), and — in severe cases — haemodynamic collapse. Risk stratification tools such as the EHRA Syncope Classification, ESC/ACC/AHA guideline-based Class I and IIa indications for pacing, and ambulatory monitoring data (Holter, implantable loop recorder) are used to confirm candidacy before any device is recommended.

A cardiac pacemaker is a pulse generator — a hermetically sealed titanium case housing a lithium-iodide battery and microprocessor — connected to one, two, or three intracardiac leads (or, in the case of leadless devices, self-contained within the right ventricle). The device continuously senses intrinsic electrical activity and delivers precisely timed stimuli only when needed, operating in internationally standardised pacing modes described by the NBG code (e.g., DDD, VVIR, AAIR). Contemporary devices incorporate rate-responsive algorithms (accelerometer- and minute-ventilation-based), magnetic resonance imaging (MRI) conditional designs, remote monitoring via Bluetooth-enabled home transmitters, and battery longevity of 8–15 years depending on pacing burden.

The global standard of care — as defined by the 2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy and the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia — mandates shared decision-making, device selection individualised to anatomy and comorbidity, and long-term follow-up in a dedicated device clinic. Leading cardiac centres in India (including Apollo Hospitals, Fortis, Medanta, and Narayana Health) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai, American Hospital Dubai) fully adhere to these guidelines, staffed by board-certified electrophysiologists and cardiac device specialists trained in North America, the United Kingdom, and Europe.

Candidates

• ELIGIBLE PATIENTS (Class I Indications per ACC/AHA/ESC):

• Symptomatic sinus node dysfunction (sick sinus syndrome, sinoatrial exit block) with documented bradycardia causing syncope, pre-syncope, or limiting fatigue

• Complete (third-degree) AV block regardless of symptoms, or second-degree Mobitz Type II AV block

• Chronic bifascicular or trifascicular block with intermittent complete AV block or symptomatic bradycardia

• Post-ablation heart block (following AV nodal ablation for atrial fibrillation with rapid ventricular response)

• Cardiac resynchronisation therapy (CRT-P/CRT-D) candidacy: symptomatic heart failure (NYHA Class II–IV), LVEF ≤35%, LBBB with QRS duration ≥150 ms on optimised guideline-directed medical therapy

• Congenital complete heart block (paediatric or adult)

• Carotid sinus hypersensitivity with cardioinhibitory response and recurrent syncope

• Neurocardiogenic (vasovagal) syncope refractory to conservative management in select cases

• REQUIRED PRE-PROCEDURE DIAGNOSTICS:

• 12-lead ECG with rhythm strip

• 24–72 hour Holter monitor or 7–14 day ambulatory ECG patch

• Transthoracic echocardiogram (Echo/TTE) to assess LV function, wall motion, and valvular anatomy

• Exercise stress test (to assess chronotropic competence and exercise-induced block)

• Blood tests: CBC, BMP/electrolytes, coagulation profile (PT/INR/aPTT), renal function (eGFR critical for contrast use), thyroid function (TSH), HbA1c

• Chest X-ray (PA and lateral views)

• Coronary angiography or CTA coronary if ischaemic aetiology is suspected

• Implantable loop recorder (ILR) data review if previously placed

• MRI brain or carotid Doppler if neurological causes of syncope are being excluded

• CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:

• Active systemic infection or bacteraemia (implantation must be deferred; risk of device-pocket or lead infection is prohibitive)

• Uncorrected coagulopathy or supratherapeutic anticoagulation without bridging protocol

• Severe peripheral vascular disease precluding subclavian/axillary venous access (alternative approaches: femoral implant, leadless device, epicardial pacing)

• Patient refusal of blood products (Jehovah's Witness): leadless or minimally invasive strategies discussed with explicit consent

• Allergy to iodine-based contrast (pre-medication protocol required; contrast-free implant possible)

• Patients requiring high-output MRI (non-conditional legacy device): upgrade or exchange discussed pre-travel

Procedure

STANDARD TRANSVENOUS PACEMAKER IMPLANTATION

The workhorse approach performed under local anaesthesia with conscious sedation. The pulse generator is implanted in a subcutaneous or submuscular pocket infraclavicularly (typically left-sided). Leads are advanced via the subclavian, axillary, or cephalic vein under fluoroscopic guidance to the right atrium (atrial lead tip at the right atrial appendage) and/or right ventricle (ventricular lead tip at the right ventricular apex or, preferably for physiological pacing, the His bundle or right ventricular outflow tract/septum). Pacing thresholds, sensing amplitudes, and impedance values are measured intra-operatively and must meet internationally accepted implant criteria before the pocket is closed.

DEVICE TYPES AND SELECTION:

• Single-chamber pacemaker (VVI/VVIR or AAI/AAIR): indicated for chronic atrial fibrillation with bradycardia (ventricular lead only) or isolated sinus node dysfunction with intact AV conduction (atrial lead only)

• Dual-chamber pacemaker (DDD/DDDR): the most commonly implanted system; maintains AV synchrony, superior haemodynamics, and reduced pacemaker syndrome; indicated for AV block with preserved sinus function

• Biventricular pacemaker / Cardiac Resynchronisation Therapy (CRT-P): adds a coronary sinus lead to pace the left ventricle simultaneously, correcting interventricular dyssynchrony in heart failure; CRT-D combines resynchronisation with defibrillation capability

• His Bundle Pacing (HBP) and Left Bundle Branch Area Pacing (LBBAP): advanced physiological pacing strategies that capture the native conduction system, producing narrow QRS complexes and superior haemodynamic outcomes compared to conventional RV apical pacing; increasingly preferred in experienced electrophysiology centres for patients with AV block and normal LVEF

• Leadless Pacemaker (Micra AV, Abbott Aveir): catheter-delivered transcatheter device implanted directly into the right ventricular myocardium via femoral vein; no subcutaneous pocket, no transvenous leads; significantly lower risk of pocket haematoma, lead dislodgement, and device-pocket infection; indicated for patients with limited venous access, prior device infections, or high bleeding risk

MINIMALLY INVASIVE / ADVANCED APPROACHES:

• Axillary vein access under ultrasound guidance: reduces pneumothorax risk compared to blind subclavian puncture; standard practice at high-volume centres

• Extravascular ICD with subcutaneous coil (for patients needing defibrillation without transvenous access)

• Concomitant catheter ablation and pacemaker implantation in the same electrophysiology laboratory session (e.g., AV nodal ablation + CRT-D for AF with heart failure)

• Remote monitoring integration (Medtronic CareLink, Abbott Merlin.net, Biotronik Home Monitoring): allows electrophysiologists to review device diagnostics, arrhythmia logs, and lead parameters from any country — directly relevant for international patients returning home post-implant

DEVICE MANUFACTURERS AVAILABLE AT PARTNER HOSPITALS:

Medtronic, Abbott (St. Jude Medical), Boston Scientific, Biotronik — all FDA/CE-marked devices with global service and remote monitoring infrastructure.

Cost of Pacemaker Implantation: India vs. UAE

The total cost of pacemaker implantation varies significantly based on device type (single-chamber versus dual-chamber versus CRT/leadless), lead technology, hospital tier, and length of stay. India offers internationally benchmarked electrophysiology expertise at 40–60% lower cost than the UAE, making it the preferred destination for cost-sensitive international patients. The UAE — particularly Dubai and Abu Dhabi — offers premium hotel-standard hospital facilities, proximity to Europe and the Middle East, and seamless travel logistics, appealing to patients who prioritise comfort and convenience. Both destinations offer JCI-accredited hospitals with FDA/CE-approved devices from Medtronic, Abbott, Boston Scientific, and Biotronik. The figures below reflect all-inclusive packages (surgeon fees, anaesthesia, device hardware, hospital stay, standard medications, and routine investigations); complex cases requiring CRT-D or leadless devices, or patients with significant comorbidities, will fall toward the higher end of the range.

Destination	Estimated Cost (USD)	Key Advantage
India	$4,000 – $9,000	~52% less than the UAE
UAE (Dubai/Abu Dhabi)	$9,000 – $18,000	Premium care, JCI/DHA accredited

Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.

Recovery & Aftercare

PRE-ARRIVAL PHASE (4–6 weeks before travel):

• GAF Healthcare coordinator reviews existing medical records (ECGs, Holter reports, Echo, angiograms) and obtains a remote clinical opinion from the treating electrophysiologist

• Device type and surgical approach confirmed; estimated cost package issued

• e-Medical Visa (India) or UAE entry visa arranged; travel insurance with cardiac coverage advised

• Patient advised to continue anticoagulants per cardiologist guidance; aspirin/clopidogrel bridging protocol communicated

DAY 1 — ARRIVAL AND PRE-OPERATIVE ASSESSMENT:

• Airport transfer to partner hospital or GAF-coordinated accommodation

• Cardiology OPD consultation: history, physical examination, review of all diagnostics

• Additional investigations if required: repeat ECG, echo, blood panel, chest X-ray

• Anaesthesia pre-assessment; consent process with translated documentation

• Nil by mouth instructions from midnight

DAY 2 — IMPLANTATION PROCEDURE (Duration: 60–120 minutes):

• Patient transferred to the electrophysiology (EP) laboratory or cardiac catheterisation suite

• IV access established; continuous ECG, pulse oximetry, and blood pressure monitoring

• Local anaesthesia administered to the infraclavicular region (or femoral vein for leadless device)

• Venous access obtained (axillary/subclavian/cephalic vein) under ultrasound and fluoroscopic guidance

• Lead(s) advanced and positioned under fluoroscopy; electrical parameters measured and optimised

• Pulse generator connected and secured in the subcutaneous/submuscular pocket; wound closed in layers

• Post-implant chest X-ray performed in the EP lab to confirm lead position and exclude pneumothorax

• Patient returned to monitored cardiac ward

DAY 2–3 — IN-HOSPITAL MONITORING:

• Continuous telemetry monitoring for minimum 24–48 hours

• Device interrogation on post-operative day 1 to confirm stable thresholds and sensing

• Wound inspection; drain (if placed) removed

• Physiotherapy: early ambulation encouraged; arm movement restrictions explained (no overhead lifting or vigorous ipsilateral arm movement for 4–6 weeks to allow lead fixation)

• Remote monitoring device (home transmitter) programmed and paired before discharge

DAY 3–4 — DISCHARGE:

• Final device interrogation and programming

• Patient and companion educated on wound care, activity restrictions, electromagnetic interference precautions (arc welders, MRI booking protocols), and pacemaker ID card issued

• Follow-up appointment scheduled for day 10–14 (wound review, suture removal, repeat device check)

• Emergency contact numbers and remote monitoring protocol provided

WEEKS 2–3 — PRE-DEPARTURE ASSESSMENT (FIT-TO-FLY CLEARANCE):

• Wound fully healed; no signs of infection, haematoma, or lead dislodgement

• Device interrogated: stable pacing thresholds, no arrhythmia alerts, battery status confirmed

• Chest X-ray repeated to confirm lead stability

• Cardiologist issues fit-to-fly letter; airline notified if supplemental oxygen or wheelchair assistance needed

• Remote monitoring transmission verified from patient's home country

• International flight cleared at approximately 2–3 weeks post-implant for uncomplicated cases

LONG-TERM RECOVERY MILESTONES:

• 4–6 weeks: full ipsilateral arm range of motion restored; light activities of daily living resumed

• 6–8 weeks: return to desk work; driving resumed (jurisdiction-specific regulations apply — typically 1–4 weeks post-implant for non-commercial driving)

• 3 months: first formal outpatient device clinic follow-up with home cardiologist; remote monitoring data shared with implanting centre via GAF Healthcare coordinator

• Annual: device clinic review; battery longevity check; lead integrity assessment

Risks & Considerations

Pacemaker implantation is considered a low-risk procedure with an overall major complication rate of approximately 1–3% at experienced, high-volume centres. Patients and families should nonetheless be counselled on the following procedure-specific and device-related risks before travel.

PERIPROCEDURAL RISKS: Pneumothorax (collapsed lung from subclavian vein puncture) occurs in approximately 1–2% of transvenous implants and may require chest tube drainage; use of ultrasound-guided axillary vein access at GAF partner hospitals significantly mitigates this risk. Haematoma formation in the device pocket (1–3%) may require aspiration or surgical evacuation, particularly in patients on anticoagulation. Lead dislodgement (0.5–2%) necessitates a return to the EP laboratory for repositioning, most commonly in the first 24–72 hours — which is why the minimum monitoring period before discharge is 48 hours. Air embolism, arterial puncture, and brachial plexus injury are rare but recognised complications of venous access.

For an uncomplicated single- or dual-chamber pacemaker implantation, most patients are cleared for international air travel approximately 2–3 weeks after the procedure. The timeline is as follows: patients are typically discharged from hospital on day 3–4 post-implant after a mandatory 24–48 hour telemetry monitoring period, a device interrogation confirming stable electrical parameters, and a chest X-ray confirming lead position. A wound review and repeat device check are performed at 10–14 days post-implant, at which point the incision should be fully healed with no signs of infection or haematoma. A final fit-to-fly assessment — including device interrogation, chest X-ray, and cardiologist sign-off — is completed at approximately 2–3 weeks, after which a formal fit-to-fly letter is issued for the airline. Patients who undergo more complex procedures (CRT implantation, concurrent ablation, or those who experience any complication) may require a longer stay of 3–4 weeks. It is important to note that altitude and cabin pressure do not interfere with modern pacemaker function; however, airport security metal detectors and full-body scanners should be navigated with the pacemaker ID card, and patients should request a manual pat-down rather than prolonged proximity to screening wand devices. GAF Healthcare coordinates all fit-to-fly documentation and communicates directly with the patient's home cardiologist to ensure seamless handover.

Pacemaker implantation is one of the most reliably successful procedures in cardiovascular medicine. At high-volume electrophysiology centres — the category of hospitals exclusively partnered with GAF Healthcare — the procedural success rate (defined as successful device implantation with lead positions meeting all electrical implant criteria in a single operative session) exceeds 98–99%. The vast majority of patients experience immediate resolution of symptomatic bradycardia, with significant improvements in exercise tolerance, syncope-free survival, and quality-of-life scores documented within 4–8 weeks of implantation. The major complication rate (pneumothorax requiring intervention, pocket haematoma requiring evacuation, lead dislodgement requiring repositioning, or device infection requiring extraction) is approximately 1–3% across all transvenous implants at experienced centres, and substantially lower for leadless pacemaker implantation with respect to pocket and lead-related complications. Long-term device reliability is also excellent: modern pacemaker generators have a 10-year failure rate of less than 0.1% when used within manufacturer-specified parameters. Battery longevity is typically 8–15 years depending on pacing percentage and output settings, and generator replacement is a planned, low-risk outpatient procedure. Remote monitoring — standard at all GAF partner hospitals — allows the implanting electrophysiologist to proactively detect any early warning signs of lead or device issues, ensuring that international patients receive the same standard of ongoing surveillance as local patients.

Why Plan Your Treatment Through Gaf Healthcare?

GAF Healthcare provides comprehensive end-to-end non-medical coordination so that patients and their families experience no administrative burden during their treatment journey.

VISA AND TRAVEL DOCUMENTATION: For treatment in India, GAF Healthcare assists patients in applying for the Indian e-Medical Visa, which is available to citizens of over 160 countries, is processed online within 1–4 business days, and permits a stay of up to 60 days (extendable). A formal hospital appointment letter — drafted on partner hospital letterhead — is provided for the visa application. One attendant (companion) e-Medical Visa is arranged simultaneously. For treatment in the UAE (Dubai or Abu Dhabi), citizens of most GCC, EU, North American, and ASEAN countries receive visa-free entry or visa-on-arrival for 30–90 days; GAF Healthcare confirms eligibility by nationality and arranges visa-on-arrival approval letters or e-Visa applications where required. All patients receive a letter from the implanting cardiologist confirming the medical nature of the visit for immigration and customs purposes (device identification card for airport security screening is also issued at discharge).

AIRPORT AND IN-COUNTRY TRANSFERS: Dedicated airport meet-and-greet service with a GAF-assigned medical escort is arranged for arrival. Wheelchair assistance and priority boarding are pre-booked for patients with significant functional impairment. All transfers between accommodation, hospital, and airport use clean, air-conditioned vehicles with a driver briefed on the patient's medical status. Post-procedure, patients are transferred in vehicles adapted for comfort to minimise wound site movement.

ACCOMMODATION: GAF Healthcare pre-negotiates accommodation at partner serviced apartments or hotels within 5–10 minutes of the treating hospital, priced for patient and one attendant. Accommodation options range from standard (budget-conscious) to premium suites, all with access to in-room meals, reliable Wi-Fi for remote monitoring transmissions, and a 24-hour helpline connected to the GAF coordinator. Extended stays (during the fit-to-fly waiting period) are arranged at reduced negotiated rates.

TRANSLATION AND COMMUNICATION: GAF Healthcare provides certified medical interpreters for Arabic, Russian, Swahili, French, Bangla, Tagalog, and other major languages at all clinical consultations, consent discussions, and discharge education sessions. Written discharge summaries, device programming reports, and remote monitoring instructions are translated into the patient's preferred language. A single dedicated GAF care coordinator — reachable by WhatsApp, telephone, and email — serves as the patient's primary point of contact from first inquiry through to the 3-month post-return device review, liaising between the implanting team and the patient's home cardiologist to ensure continuity of care.

Patients Also Explore

Other treatments commonly sought by patients considering Pacemaker Implantation.

Breast Cancer Treatment

Cancer Care

Lung Cancer Treatment

Cancer Care

Brain Tumor Surgery

Neurology

Deep Brain Stimulation

Neurology

The arterial switch operation (TGA repair) in India costs USD 5,500–9,000 with a 94–97% survival rate. Complete guide covering the procedure, best hospitals, recovery timeline, and how GAF Healthcare coordinates surgery from abroad.

Read Guide